Anthem Biosciences Ltd (ANTHEM) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 10039665, "name": "Anthem Bioscienc", "stock_name": "Anthem Bioscienc", "full_name": "Anthem Biosciences Ltd", "name_url": "stocks-analysis/anthem-bioscienc", "exchange": 1, "exchangecode": "", "primexch": 1, "country_id": 34, "currency": "INR", "cmp": "765.35", "chg": -11.75, "chgp": "-1.51%", "dir": -1, "prev_price": "777.10", "mcapval": "44,104.00 Cr", "mcap": "Mid Cap", "scripcode": 544449, "symbol": "ANTHEM", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "indexname": "India SENSEX", "isin": "INE0CZ201020", "curr_date": "May 25", "curr_time": "", "bse_nse_vol": "4.23 lacs", "exc_status": "Active", "traded_date": "May 25, 2026", "traded_date_str": "2026 05 25", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-registerF-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/anthem-bioscienc-10039665-1&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "Anthem Biosciences Ltd’s Mixed Week: -0.89% Price Change Amid Technical Shifts and Quality Upgrade", "link": "https://www.marketsmojo.com/news/stocks-in-action/anthem-biosciences-ltds-mixed-week--089-price-change-amid-technical-shifts-and-quality-upgrade-4007658", "imagepath": "", "date": "2026-05-23 09:04:42", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>18 May:</strong> Stock opens at ₹789.95, up 0.82% despite Sensex decline</p>\n <p><strong>19 May:</strong> Downgrade to Sell announced amid technical weakness and financial setbacks</p>\n <p><strong>20 May:</strong> Formation of Golden Cross signals potential bullish breakout</p>\n <p><strong>21 May:</strong> Technical momentum shifts to mildly bullish despite price decline</p>\n <p><strong>22 May:</strong> Quality grade upgraded to Excellent; rating upgraded to Buy</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</..." }, { "title": "Anthem Biosciences Ltd Upgraded to Buy on Strong Financial and Quality Improvements", "link": "https://www.marketsmojo.com/news/stock-recommendation/anthem-biosciences-ltd-upgraded-to-buy-on-strong-financial-and-quality-improvements-4004534", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/AnthemBioscienc_mojoScore_4004534.png", "date": "2026-05-22 08:25:49", "description": "Anthem Biosciences Ltd has seen a significant upgrade in its investment rating from Sell to Buy as of 21 May 2026, driven by marked improvements across financial performance, quality metrics, valuation considerations, and technical indicators. This mid-cap pharmaceutical and biotechnology company’s recent quarterly results and long-term fundamentals have prompted a reassessment of its prospects, positioning it favourably against sector peers and broader market benchmarks." }, { "title": "Anthem Biosciences Ltd Upgrades Quality Grade to Excellent Amid Strong Financial Metrics", "link": "https://www.marketsmojo.com/news/stocks-in-action/anthem-biosciences-ltd-upgrades-quality-grade-to-excellent-amid-strong-financial-metrics-4004174", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/AnthemBioscienc_qualitydot_4004174.png", "date": "2026-05-22 08:00:20", "description": "Anthem Biosciences Ltd has seen a significant upgrade in its quality grading from good to excellent, reflecting marked improvements in its business fundamentals. The pharmaceutical and biotechnology company’s robust sales and EBIT growth, alongside stellar returns on capital and equity, underpin this positive reassessment. Despite a slight dip in share price, the company’s financial health and operational efficiency position it favourably against peers and broader market benchmarks." }, { "title": "Has Anthem Biosciences Ltd declared dividend?", "link": "https://www.marketsmojo.com/news/stocks-in-action/has-anthem-biosciences-ltd-declared-dividend-4004046", "imagepath": "", "date": "2026-05-21 23:31:36", "description": "Anthem Biosciences Ltd has declared a 100% dividend.\n\nDividend Details:\nPercentage announced: 100%\nEx-date: 25 Jun 26\n\nDividend Yield: 0%\n\nTotal Returns by Period:\nIn the last 3 months, Anthem Biosciences Ltd achieved a price return of 13.0%, a dividend return of 0.29%, resulting in a total return of 13.29%.\n\nOver the past 6 months, the company recorded a price return of 21.11%, a dividend return of 0.32%, leading to a total return of 21.43%.\n\nFor the 1-year period, there was no price return or dividend return, resulting in a total return of 0.0%.\n\nIn the 2-year period, the company saw no price return or dividend return, culminating in a total return of 0.0%.\n\nOver the last 3 years, there were no price or dividend returns, resulting in a total return of 0.0%.\n\nIn the 4-year period, there was no price return or dividend return, leading to a total return of 0.0%.\n\nFinally, in the 5-year period, there were no ..." }, { "title": "Are Anthem Biosciences Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-anthem-biosciences-ltd-latest-results-good-or-bad-4003660", "imagepath": "", "date": "2026-05-21 19:31:16", "description": "Anthem Biosciences Ltd reported its Q4 FY26 results, showcasing significant operational achievements. The company recorded a net profit of ₹189.76 crores, reflecting a notable increase compared to the previous quarter, where it was ₹92.82 crores. This performance indicates a strong recovery from the subdued results of the prior quarter. Revenue for the same quarter reached ₹610.94 crores, marking a substantial rise from ₹423.15 crores in Q3 FY26. This quarter also saw the highest sales in the company's history, with a sequential growth of 44.38% and a year-on-year growth of 26.44%.\n\nThe operating margin improved to 43.74%, up from 37.15% in the previous quarter, indicating enhanced operational efficiency. Additionally, the return on equity (ROE) stood at 24.12%, reflecting strong capital efficiency. The company’s performance was bolstered by effective cost management and a favorable project mix, leading to ..." }, { "title": "Anthem Biosciences Ltd Technical Momentum Shifts to Mildly Bullish Amid Mixed Market Returns", "link": "https://www.marketsmojo.com/news/stocks-in-action/anthem-biosciences-ltd-technical-momentum-shifts-to-mildly-bullish-amid-mixed-market-returns-4002245", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/AnthemBioscienc_technicaldot_4002245.png", "date": "2026-05-21 08:04:48", "description": "Anthem Biosciences Ltd, a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bearish to a mildly bullish trend. Despite a recent day decline of 0.87%, the stock’s technical indicators reveal a complex picture of emerging strength tempered by caution, as investors weigh the implications of mixed signals from key momentum and volume metrics." }, { "title": "Anthem Biosciences Q4 FY26: Strong Quarter Masks Valuation Concerns", "link": "https://www.marketsmojo.com/news/result-analysis/anthem-biosciences-q4-fy26-strong-quarter-masks-valuation-concerns-4001577", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/AnthemBioscienc_quaterlyResult_4001577.png", "date": "2026-05-20 19:34:11", "description": "Anthem Biosciences Ltd., a mid-cap pharmaceuticals and biotechnology company with a market capitalisation of ₹45,142 crores, delivered a blockbuster performance in Q4 FY26 (March 2026 quarter), posting net profit of ₹189.76 crores—a stunning 104.44% surge quarter-on-quarter and 129.68% year-on-year growth. However, the stock declined 0.87% to ₹780.25 following the results announcement, reflecting investor concerns over stretched valuations despite the impressive operational performance." }, { "title": "Golden Cross Forms in Anthem Biosciences Ltd — Mixed Technical Signals Cloud the Outlook", "link": "https://www.marketsmojo.com/news/stocks-in-action/anthem-biosciences-ltd-forms-golden-cross-signalling-potential-bullish-breakout-4001423", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/AnthemBioscienc_goldencross_4001423.png", "date": "2026-05-20 18:00:43", "description": "The 50-day moving average has crossed above the 200-day moving average for Anthem Biosciences Ltd, signalling a golden cross on 20 May 2026. Yet, the stock declined 0.87% on the day the cross formed, while monthly technical indicators remain inconclusive. This divergence between the moving averages and other signals calls for a nuanced analysis of the cross's reliability." }, { "title": "Anthem Biosciences Downgraded to Sell Amid Technical Weakness and Financial Setbacks", "link": "https://www.marketsmojo.com/news/stock-recommendation/anthem-biosciences-downgraded-to-sell-amid-technical-weakness-and-financial-setbacks-3998462", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/AnthemBioscienc_mojoScore_3998462.png", "date": "2026-05-19 09:11:12", "description": "Anthem Biosciences Ltd, a mid-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 18 May 2026. This shift reflects a combination of deteriorating technical indicators, disappointing quarterly financial results, and valuation concerns, despite some positive long-term fundamentals and institutional interest." } ], "total": 47, "sid": "10039665", "stock_news_url": "https://www.marketsmojo.com/news/anthem-biosciences-10039665" }, "announcements": "", "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Anthem Biosciences Ltd has declared <strong>100%</strong> dividend, ex-date: 25 Jun 26", "dt": "2026-06-25", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

18 May: Stock opens at ₹789.95, up 0.82% despite Sensex decline

19 May: Downgrade to Sell announced amid technical weakness and financial setbacks

20 May: Formation of Golden Cross signals potential bullish breakout

21 May: Technical momentum shifts to mildly bullish despite price decline

22 May: Quality grade upgraded to Excellent; rating upgraded to Buy

Week OpenRead full news article

Anthem Biosciences Ltd Upgraded to Buy on Strong Financial and Quality Improvements

2026-05-22 08:25:49

Anthem Biosciences Ltd has seen a significant upgrade in its investment rating from Sell to Buy as of 21 May 2026, driven by marked improvements across financial performance, quality metrics, valuation considerations, and technical indicators. This mid-cap pharmaceutical and biotechnology company’s recent quarterly results and long-term fundamentals have prompted a reassessment of its prospects, positioning it favourably against sector peers and broader market benchmarks.

Read full news article

Anthem Biosciences Ltd Upgrades Quality Grade to Excellent Amid Strong Financial Metrics

2026-05-22 08:00:20

Anthem Biosciences Ltd has seen a significant upgrade in its quality grading from good to excellent, reflecting marked improvements in its business fundamentals. The pharmaceutical and biotechnology company’s robust sales and EBIT growth, alongside stellar returns on capital and equity, underpin this positive reassessment. Despite a slight dip in share price, the company’s financial health and operational efficiency position it favourably against peers and broader market benchmarks.

Read full news article

Has Anthem Biosciences Ltd declared dividend?

2026-05-21 23:31:36

Anthem Biosciences Ltd has declared a 100% dividend. Dividend Details: Percentage announced: 100% Ex-date: 25 Jun 26 Dividend Yield: 0% Total Returns by Period: In the last 3 months, Anthem Biosciences Ltd achieved a price return of 13.0%, a dividend return of 0.29%, resulting in a total return of 13.29%. Over the past 6 months, the company recorded a price return of 21.11%, a dividend return of 0.32%, leading to a total return of 21.43%. For the 1-year period, there was no price return or dividend return, resulting in a total return of 0.0%. In the 2-year period, the company saw no price return or dividend return, culminating in a total return of 0.0%. Over the last 3 years, there were no price or dividend returns, resulting in a total return of 0.0%. In the 4-year period, there was no price return or dividend return, leading to a total return of 0.0%. Finally, in the 5-year period, there were no ...

Read full news article

Are Anthem Biosciences Ltd latest results good or bad?

2026-05-21 19:31:16

Anthem Biosciences Ltd reported its Q4 FY26 results, showcasing significant operational achievements. The company recorded a net profit of ₹189.76 crores, reflecting a notable increase compared to the previous quarter, where it was ₹92.82 crores. This performance indicates a strong recovery from the subdued results of the prior quarter. Revenue for the same quarter reached ₹610.94 crores, marking a substantial rise from ₹423.15 crores in Q3 FY26. This quarter also saw the highest sales in the company's history, with a sequential growth of 44.38% and a year-on-year growth of 26.44%. The operating margin improved to 43.74%, up from 37.15% in the previous quarter, indicating enhanced operational efficiency. Additionally, the return on equity (ROE) stood at 24.12%, reflecting strong capital efficiency. The company’s performance was bolstered by effective cost management and a favorable project mix, leading to ...

Read full news article

Anthem Biosciences Ltd Technical Momentum Shifts to Mildly Bullish Amid Mixed Market Returns

2026-05-21 08:04:48

Anthem Biosciences Ltd, a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bearish to a mildly bullish trend. Despite a recent day decline of 0.87%, the stock’s technical indicators reveal a complex picture of emerging strength tempered by caution, as investors weigh the implications of mixed signals from key momentum and volume metrics.

Read full news article

Anthem Biosciences Q4 FY26: Strong Quarter Masks Valuation Concerns

2026-05-20 19:34:11

Anthem Biosciences Ltd., a mid-cap pharmaceuticals and biotechnology company with a market capitalisation of ₹45,142 crores, delivered a blockbuster performance in Q4 FY26 (March 2026 quarter), posting net profit of ₹189.76 crores—a stunning 104.44% surge quarter-on-quarter and 129.68% year-on-year growth. However, the stock declined 0.87% to ₹780.25 following the results announcement, reflecting investor concerns over stretched valuations despite the impressive operational performance.

Read full news article

Golden Cross Forms in Anthem Biosciences Ltd — Mixed Technical Signals Cloud the Outlook

2026-05-20 18:00:43

The 50-day moving average has crossed above the 200-day moving average for Anthem Biosciences Ltd, signalling a golden cross on 20 May 2026. Yet, the stock declined 0.87% on the day the cross formed, while monthly technical indicators remain inconclusive. This divergence between the moving averages and other signals calls for a nuanced analysis of the cross's reliability.

Read full news article

Anthem Biosciences Downgraded to Sell Amid Technical Weakness and Financial Setbacks

2026-05-19 09:11:12

Anthem Biosciences Ltd, a mid-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 18 May 2026. This shift reflects a combination of deteriorating technical indicators, disappointing quarterly financial results, and valuation concerns, despite some positive long-term fundamentals and institutional interest.

Read full news article